Illumina Stock News

JGP Wealth Management LLC boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 7.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,511 shares of the life sciences companys stock after purchasing an additional 107 shares during the quarter. JGP Wealth Management LLCs holdings in []

IFM Investors Pty Ltd reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,959 shares of the life sciences companys stock after selling 63 shares during the period. IFM Investors Pty []

Marshall Wace North America L.P. lowered its holdings in Illumina, Inc. (NASDAQ:ILMN) by 38.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,914 shares of the life sciences companys stock after selling 1,217 shares during the period. Marshall Wace North America L.P.s holdings []

Illumina's (ILMN) Genomics Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics.

Precisely figuring out toxic stocks and discarding or short selling those at the right time is the key to safeguarding your portfolio from big losses.

Global Mutational Analysis Market Synopsis: An entire Mutational Analysis Market report is spread across more than 350 pages, list of tables & figures, profiling more than ten companies. Analysis and estimations attained through the massive information gathered in this Market report

Analysts expect that Illumina, Inc. (NASDAQ:ILMN) will post $0.50 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Illuminas earnings, with the lowest EPS estimate coming in at $0.40 and the highest estimate coming in at $0.68. Illumina posted earnings of $1.22 per share during []

New Jersey, United Kingdom, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled "Consumer Genomics Market By Application (Diagnostics, Genetic Relatedness, Nutrition, Wellness, & Lifestyle, Reproductive Health, Ancestry, Sports Nutrition & Health, Pharmacogenetic Testing, Personalized Medicine, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 2026" in its research database "According to the latest research study, the demand of global Consumer Genomics Market size & share expected to reach to USD 5,230 Million by 2026 from USD 1,440 Million in 2019, at a compound annual growth rate (CAGR) of 20.2% during the forecast period 2020 to 2026" What is Consumer Genomics? Report Overview & Coverage: Consumer genomics is a stream of genomics that includes the sampling, analysis, and description of a person''s genome. The consumer genomics sector is evolving steadily and rapidly into a normal view. Market genomics has a large role to play in pushing forward new concepts and their implementations to the majority.

The Next Generation Sequencing (NGS) Product Market research report presents a top-notch analysis that incorporates market restaurants, drivers, and opportunities available in the market. The report also segments the market by how a competitive environment is developed among leading players

The Companion Diagnostics for Oncology Market research report focuses on consolidations and acquisitions, extensions, examination of central participants, the foundation date of organization regions served, fabricating base, and income of vital participants. Moreover, the report also studies breakdown by product

First use of the European Commissions new referral policy and failure by the parties to comply with their standstill obligation. Please see full Publication below for more information. By: Allen & Overy LLP

DUBLIN--(BUSINESS WIRE)--The "Global Cancer Microbiome Sequencing Market - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com''s offering. The market is driven by certain factors, which include increasing emphasis on the microbiome''s potential in the field of cancer, growing cancer prevalence, and decreasing cost of sequencing are fueling the growth of the global cancer microbiome sequencing market. Companies Mentioned Cosmos ID Illumina, Inc. Invivo Diagnostics Me

SAN DIEGO, Nov. 17, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Sequoia Capital China, a leading investment firm, today jointly announced the selection of the first two startup companies joining the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by

DUBLIN--(BUSINESS WIRE)--The "Lung Cancer Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com''s offering. Amid the COVID-19 crisis, the global market for Lung Cancer Diagnostics estimated at US$2.5 Billion in the year 2020, is projected to reach a revised size of US$4.3 Billion by 2027, growing at a CAGR of 8.1% over the analysis period 2020-2027. Imaging Tests, one of the segments analyzed in the report, is projected to grow at a 8% CAGR to r